Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.47 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | MGAM | O43451 | 2/20 | 0.45 |
| ▸ | SI | P14410 | 2/20 | 0.45 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1170768 | 0.83 | ADORA1 (0.61) | PSMB8NPC1RAB9AADORA1ADORA3 | |
| SCHEMBL8956421 | 0.79 | NPC1 (0.50) | PSMB8NPC1RAB9AADORA1ADORA3 | |
| SCHEMBL3109602 | 0.79 | MGAM (0.60) | NPC1RAB9AGAAMGAMSI | |
| SCHEMBL3973619 | 0.79 | NPC1 (0.50) | PSMB8NPC1RAB9AADORA1ADORA3 | |
| SCHEMBL215756 | 0.79 | NUDT1 (0.70) | PSMB8ADORA1ADORA3MAOBADORA2A | |
| SCHEMBL9305483 | 0.79 | RAB9A (0.50) | PSMB8NPC1RAB9AGAAMGAM | |
| SCHEMBL11739880 | 0.79 | PSMB8 (0.56) | PSMB8NPC1RAB9AADORA1ADORA3 | |
| SCHEMBL6843925 | 0.79 | NPC1 (0.50) | PSMB8NPC1RAB9ANUDT1GAA | |
| SCHEMBL6118216 | 0.79 | GAA (0.54) | PSMB8NPC1RAB9ANUDT1GAA | |
| SCHEMBL31534795 | 0.79 | PSMB8 (0.56) | PSMB8NPC1RAB9AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 366 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118126467-A | Heat-resistant modified polyvinyl chloride power tube and preparation method thereof | 杭州鼎新建科实业有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-111335033-A | Neckerchief fabric for infant care and preparation method thereof | 张海军 | 2020-06-26 | — | — | CN | claimed |
| US-8188254-B2 | C-class oligonucleotide analogs with enhanced immunostimulatory potency | COLEY PHARMACEUTICAL GMBH (DE) | 2012-05-29 | — | — | US | claimed |
| EP-1978997-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | Apollo Life Sciences Limited (AU) | 2008-10-15 | — | — | EP | claimed |
| WO-2007070983-A1 | TRANSDERMAL DELIVERY OF PHARMACEUTICAL AGENTS | APOLLO LIFE SCIENCES LIMITED (AU) | 2007-06-28 | — | — | WO | claimed |
| EP-1730281-A2 | IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING IL-10 RESPONSES | Coley Pharmaceutical Group, Inc. (US) | 2006-12-13 | — | — | EP | claimed |
| EP-1728863-A2 | C-class oligonucleotide analogs with enhanced immunostimulatory potency | Coley Pharmaceutical GmbH (DE) | 2006-12-06 | — | — | EP | claimed |
| EP-1678303-A2 | C-CLASS OLIGONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY POTENCY | Coley Pharmaceutical GmbH (DE) | 2006-07-12 | — | — | EP | claimed |
| WO-2005111057-A2 | IMMUNOSTIMULATORY NUCLEIC ACIDS FOR INDUCING IL-10 RESPONSES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2005-11-24 | — | — | WO | claimed |
| US-20050239734-A1 | C-class oligonucleotide analogs with enhanced immunostimulatory potency | COLEY PHARMACEUTICAL GMBH (DE) | 2005-10-27 | — | — | US | claimed |
| EP-1578954-A2 | 5' CPG NUCLEIC ACIDS AND METHODS OF USE | Coley Pharmaceutical Group, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| WO-2005042018-A2 | C-CLASS OLIGONUCLEOTIDE ANALOGS WITH ENHANCED IMMUNOSTIMULATORY POTENCY | COLEY PHARMACEUTICAL GMBH (DE) | 2005-05-12 | — | — | WO | claimed |
| US-20040171571-A1 | 5' CpG nucleic acids and methods of use | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-09-02 | — | — | US | claimed |
| WO-2004053104-A2 | 5’ CPG NUCLEIC ACIDS AND METHODS OF USE | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-06-24 | — | — | WO | claimed |
| US-12637646-B2 | DNA origami cell sensing platform | OHIO STATE INNOVATION FOUNDATION (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260139247-A1 | ENGINEERED ENVELOPED VECTORS AND METHODS OF USE THEREOF | GIGAMUNE INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-12631621-B2 | Ligand discovery and gene delivery via retroviral surface display | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-05-19 | — | — | US | disclosed |
| WO-2004016805-A2 | IMMUNOSTIMULATORY NUCLEIC ACIDS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-02-26 | — | — | WO | disclosed |
| WO-2004005476-A2 | NUCLEIC ACID COMPOSITIONS FOR STIMULATING IMMUNE RESPONSES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| US-4594420-A | Substituted with bromine or chlorine | HOECHST AKTIENGESELLSCHAFT (DE) | 1986-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139247-A1 | ENGINEERED ENVELOPED VECTORS AND METHODS OF USE THEREOF | TMIGD3, TMPRSS11D, TMED2 | PSMB8 1707/4885NPC1 197/4885RAB9A 3159/4885 |
| US-12637646-B2 | DNA origami cell sensing platform | DNMT3A, EPCAM, CASR | PSMB8 4724/4885NPC1 2283/4885RAB9A 4492/4885 |
| US-12631621-B2 | Ligand discovery and gene delivery via retroviral surface display | TMIGD3, LDLR, VSIG8 | PSMB8 3809/4885NPC1 745/4885RAB9A 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.